Jeffrey Lieberman

Why Is Jeffrey Lieberman Influential?

According to Wikipedia, Jeffrey Alan Lieberman is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience and pharmacological treatment . He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing pharmacotherapies for schizophrenia. He was president of the American Psychiatric Association from May 2013 to May 2014.

Jeffrey Lieberman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Biological Insights From 108 Schizophrenia-Associated Genetic Loci (5946)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. (4976)
Practice guideline for the treatment of patients with schizophrenia, second edition. (1960)
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs (1886)
Genome-wide association study identifies five new schizophrenia loci (1611)
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. (1153)
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. (1127)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III (1109)
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. (944)
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. (902)
Duration of psychosis and outcome in first-episode schizophrenia. (901)
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. (868)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. (830)
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. (825)
Physical health monitoring of patients with schizophrenia. (809)
A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (775)
Brain volume in first-episode schizophrenia (770)
Catching Up on Schizophrenia Natural History and Neurobiology (758)
Antipsychotic drug effects on brain morphology in first-episode psychosis. (729)
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. (709)
Microduplications of 16p11.2 are Associated with Schizophrenia (656)
A national study of violent behavior in persons with schizophrenia. (641)
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways (632)
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects (623)
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. (580)
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. (570)
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. (561)
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia (560)
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches (529)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. (517)
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline (514)
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls (496)
Longitudinal study of brain morphology in first episode schizophrenia (482)
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. (464)
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. (463)
How mental health care should change as a consequence of the COVID-19 pandemic (461)
Implications for the neural basis of social cognition for the study of schizophrenia. (460)
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial (449)
Provocative tests with psychostimulant drugs in schizophrenia (444)
Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective (443)
Time course and biologic correlates of treatment response in first-episode schizophrenia. (442)
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes (433)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (426)
Barriers to employment for people with schizophrenia. (421)
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. (397)
Regional Gray Matter Growth, Sexual Dimorphism, and Cerebral Asymmetry in the Neonatal Brain (385)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. (384)
Imaging endogenous dopamine competition with [11C]raclopride in the human brain (382)
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. (379)
Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver (364)
Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain (358)
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. (344)
Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia (337)
Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity (337)
Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. (335)
Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia (330)
Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine (329)
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. (325)
Depression in first-episode schizophrenia. (311)
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. (308)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia (305)
Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. (305)
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. (302)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (302)
A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial (300)
Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. (298)
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. (293)
International clinical practice guidelines for early psychosis (280)
Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. (279)
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. (273)
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. (273)
Apoptotic mechanisms and the synaptic pathology of schizophrenia (271)
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder (271)
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 (270)
The Effects of Clozapine on Tardive Dyskinesia (269)
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. (268)
Shape analysis of brain ventricles using SPHARM (268)
Tardive dyskinesia: prevalence, incidence, and risk factors. (268)
Update on the clinical efficacy and side effects of clozapine. (261)
Genomewide association for schizophrenia in the CATIE study: results of stage 1 (257)
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. (256)
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. (254)
Measurement of Brain Metabolites by 1H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis (253)
Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland (247)
Psychosocial treatment for first-episode psychosis: a research update. (242)
Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine (239)
Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. (236)
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. (231)
Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients (230)
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. (229)
Clozapine: guidelines for clinical management. (226)
Prospective study of tardive dyskinesia in the elderly: rates and risk factors. (225)
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. (224)
Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. (223)
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study (218)
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. (217)
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. (216)
Extrapyramidal side-effects of antipsychotics in a randomised trial (215)
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection (212)
Effects of clozapine on auditory event-related potentials in schizophrenia (211)
Dopamine Partial Agonists (208)
Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder (207)
Serotonergic basis of antipsychotic drug effects in schizophrenia (206)
Statistical shape analysis of neuroanatomical structures based on medial models (206)
Integrating incidence and prevalence of tardive dyskinesia. (206)
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. (202)
Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood (199)
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. (199)
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. (198)
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder (196)
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. (195)
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. (195)
Shape versus Size: Improved Understanding of the Morphology of Brain Structures (195)
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome (195)
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function (193)
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. (190)
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol (189)
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. (188)
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol (185)
Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia (181)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. (179)
Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia (178)
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. (175)
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery (174)
Psychobiologic Correlates of Treatment Response in Schizophrenia (173)
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia (172)
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association (172)
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia (172)
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). (171)
Apoptotic mechanisms in the pathophysiology of schizophrenia (171)
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. (170)
Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol (170)
Relationship of cognition and psychopathology to functional impairment in schizophrenia. (169)
Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. (169)
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. (169)
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. (167)
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia (165)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. (164)
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory (163)
Prospective study of tardive dyskinesia incidence in the elderly. (163)
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia (162)
Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia (159)
The prevalence of tardive dyskinesia. (158)
Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. (158)
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study (157)
Effectiveness of switching antipsychotic medications. (156)
Postictal and chronic psychoses in patients with temporal lobe epilepsy. (154)
Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia (154)
Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. (153)
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. (153)
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs (153)
Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. (152)
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic (151)
Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics (151)
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode (150)
Science and recovery in schizophrenia. (150)
Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. (150)
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. (149)
A comprehensive analysis of 22q11 gene expression in the developing and adult brain (149)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia (147)
Substance Use in Persons With Schizophrenia: Baseline Prevalence and Correlates From the NIMH CATIE Study (147)
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis (146)
Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention (146)
A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia (146)
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia (145)
Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial (144)
Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics (142)
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. (139)
CATIE and CUtLASS: can we handle the truth? (138)
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. (138)
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings (137)
The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer’s Disease (134)
Tardive dyskinesia: prevalence, incidence, and risk factors. (133)
Delayed detection of psychosis: causes, consequences, and effect on public health. (133)
Neurochemistry and neuroendocrinology of schizophrenia: a selective review. (131)
Cognitive Development in Schizophrenia: Follow-Back from the First Episode (131)
Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents (131)
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles (130)
Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia (129)
Results of phase 3 of the CATIE schizophrenia trial (128)
Does clozapine cause tardive dyskinesia? (128)
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. (127)
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. (126)
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders (125)
The Mount Sinai conference on the pharmacotherapy of schizophrenia. (125)
The natural history and pathophysiology of treatment resistant schizophrenia. (125)
Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects (121)
Olanzapine and haloperidol in first episode psychosis: Two-year data (119)
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis (117)
The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics (117)
Suicidal ideation and suicide attempts among adults with psychotic experiences: data from the Collaborative Psychiatric Epidemiology Surveys. (116)
Genomewide association for schizophrenia in the CATIE study: results of stage 1 (116)
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. (116)
Time-lapse mapping of cortical changes in schizophrenia with different treatments. (115)
Effects of risperidone on auditory event-related potentials in schizophrenia. (115)
Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia (113)
Boundary and Medial Shape Analysis of the Hippocampus in Schizophrenia (112)
Schizophrenia: new pathological insights and therapies. (112)
Insight in first-episode psychosis (112)
What CATIE found: results from the schizophrenia trial. (112)
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. (111)
Qualitative assessment of brain morphology in acute and chronic schizophrenia. (109)
Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. (109)
Recent advances in the neurobiology of schizophrenia. (108)
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. (107)
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia (106)
Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). (106)
Abnormalities of the septum pellucidum on MR scans in first-episode schizophrenic patients. (106)
Olanzapine increases allopregnanolone in the rat cerebral cortex (105)
Striatal enlargement in rats chronically treated with neuroleptic (104)
Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia (103)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (103)
Auditory P300 in high-risk, recent-onset and chronic schizophrenia (102)
Placebo response in antipsychotic clinical trials: a meta-analysis. (101)
Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs (101)
The deficit state in first-episode schizophrenia. (101)
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. (101)
Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice (101)
Maximizing clozapine therapy: managing side effects. (100)
Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients (100)
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia (100)
Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations (99)
From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone (99)
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia (99)
Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. (99)
Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. (98)
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway (98)
Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization (98)
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. (96)
Prediction of relapse in schizophrenia. (96)
The NIMH-CATIE Schizophrenia Study: what did we learn? (95)
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. (95)
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. (94)
Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. (94)
Understanding the Mechanism of Action of Atypical Antipsychotic Drugs (93)
Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia (93)
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study (92)
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study (91)
A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia (91)
Antipsychotic medication effects on neuropsychological functions. (91)
The evaluation and treatment of first-episode psychosis. (90)
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. (90)
Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. (89)
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia (88)
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. (87)
Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects (87)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation (87)
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. (86)
Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia (85)
Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. (85)
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial (85)
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). (84)
Cerebellar volume asymmetries are related to handedness: A quantitative MRI study (84)
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample (83)
An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. (83)
NCAM1 and Neurocognition in Schizophrenia (82)
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder (82)
HLA associations in clozapine-induced agranulocytosis. (81)
15. Follow up MRI study in first episode schizophrenia (81)
Genome-wide association study of antipsychotic induced QTc interval prolongation (81)
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction (79)
Methylphenidate challenge as a predictor of relapse in schizophrenia. (79)
Components and correlates of family burden in schizophrenia. (78)
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. (78)
Clinical profile of clozapine: Adverse reactions and agranulocytosis (77)
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. (77)
Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. (77)
Measuring outcome priorities and preferences in people with schizophrenia (76)
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder (76)
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial (76)
Neuroprotection in schizophrenia. (76)
Myocarditis during clozapine treatment. (75)
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. (74)
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. (73)
The Development of Treatment Resistance in Patients With Schizophrenia: A Clinical and Pathophysiologic Perspective (73)
Antipsychotic Drugs for First-Episode Schizophrenia (72)
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. (72)
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. (72)
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1 (71)
Olanzapine versus haloperidol in the treatment of first episode psychosis (71)
Molecular pathophysiology of metabolic effects of antipsychotic medications (71)
Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers (70)
Perinatal Neurosteroid Levels Influence GABAergic Interneuron Localization in Adult Rat Prefrontal Cortex (70)
Diabetes and development of tardive dyskinesia. (70)
Genetic variation of 5-HT2A receptor and response to clozapine (70)
Rechallenge in clozapine-induced agranulocytosis (69)
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions (69)
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. (68)
Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. (68)
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response (68)
Enduring effects of prenatal cocaine administration on emotional behavior in rats (68)
Presynaptic regulation of dopamine transmission in schizophrenia. (68)
Mechanisms of Working Memory Impairment in Schizophrenia (68)
Complement genes contribute sex-biased vulnerability in diverse illnesses (66)
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: Candidate mechanism for superior efficacy? (66)
Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. (66)
The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. (66)
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. (65)
Dexamethasone suppression tests in patients with panic disorder. (65)
Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first‐episode schizophrenia (65)
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant (65)
Predictors of response to clozapine. (64)
Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia (62)
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial (62)
The association between weight change and symptom reduction in the CATIE schizophrenia trial (62)
Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia (62)
Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia (61)
Prevalence of tardive dyskinesia in elderly samples. (61)
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. (61)
BRAIN MORPHOLOGY IN FIRST EPISODE SCHIZOPHRENIA (61)
The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain (61)
Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. (61)
Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. (61)
Tricyclic antidepressant and metabolite levels in chronic renal failure (61)
Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain (61)
Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia (61)
Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia (60)
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. (60)
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. (59)
Association study of dopamine D3 receptor gene and schizophrenia. (59)
Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia (58)
Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders (58)
Cerebral morphometry and clozapine treatment in schizophrenia. (58)
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial (58)
A case report of cimetidine-induced clozapine toxicity. (58)
Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics (58)
A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial (57)
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations (57)
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. (56)
Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia (56)
11. Neuropsychological deficits in the early course of first episode schizophrenia (56)
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study (55)
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. (55)
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. (55)
Neurobiology and the natural history of schizophrenia. (55)
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis (55)
Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function (54)
Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes (54)
22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome (53)
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy (53)
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene (53)
Neuroprotection: A New Strategy in the Treatment of Schizophrenia (53)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia (52)
Duration of untreated psychosis and time to treatment response for delusions and hallucinations. (52)
Clinical implications of clozapine discontinuation: report of an NIMH workshop. (52)
Clozapine as a first treatment for schizophrenia. (52)
Quantitative characterization of eye tracking dysfunction in schizophrenia (51)
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. (51)
Cross-tapering clozapine and risperidone. (50)
Treatment outcome of first episode schizophrenia. (50)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia (50)
Clozapine-Induced Agranulocytosis (50)
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. (49)
Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients (49)
Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats (49)
The American Psychiatric Publishing textbook of schizophrenia (49)
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. (49)
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial (49)
Psychotic Disorders. (48)
Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors (48)
Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls (48)
Adverse effects of psychotropic drugs (48)
Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. (48)
Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. (48)
Introduction-Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia (48)
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response (47)
Hippocampal Shape and Volume Changes with Antipsychotics in Early Stage Psychotic Illness (47)
Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication (47)
Polypharmacy in fatal clozapine-associated agranulocytosis (46)
Schizophrenia (maintenance treatment). (46)
Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy (46)
A selective review of biological markers in schizophrenia. (45)
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. (45)
Prediction of outcome in first-episode schizophrenia. (45)
Redefining the role of psychiatry in medicine. (45)
Absence of the Adhesio Interthalamica as a Marker of Early Developmental Neuropathology in Schizophrenia: An MRI and Postmortem Histologic Study (44)
Early detection and intervention in schizophrenia: a new therapeutic model. (44)
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia (44)
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. (44)
Agranulocytosis: incidence and risk factors. (44)
HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis (44)
Cognitive impairment in tardive dyskinesia (43)
Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. (43)
Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia. (43)
The usefulness and use of second-generation antipsychotic medications: Review of evidence and recommendations by a Task Force of the World Psychiatric Association. (43)
Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort (42)
Tardive dyskinesia induced by risperidone? (42)
Reversed cerebellar asymmetry in men with First-Episode schizophrenia (42)
Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases (42)
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. (42)
A Report of Clozapine-Induced Agranulocytosis in the United States (41)
Ethics in psychiatric research : a resource manual for human subjects protection (41)
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials (41)
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. (40)
Methylphenidate and neuroleptic effects on oral word production in schizophrenia (40)
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. (40)
The impact of obesity on health care costs among persons with schizophrenia. (40)
Intrinsic Regression Models for Manifold-Valued Data. (39)
Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial (39)
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia (39)
Clozapine effects on tardive dyskinesia. (39)
Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. (38)
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis (37)
Schizophrenia and substance abuse. (37)
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. (37)
COMT158 polymorphism and hostility (37)
Macroscopic fast neuronal oscillations and synchrony in schizophrenia. (36)
C9ORF72 repeat expansions not detected in a group of patients with schizophrenia (36)
Caspase-3 Activation in Rat Frontal Cortex Following Treatment with Typical and Atypical Antipsychotics (36)
A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. (36)
Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects (36)
Association of RGS2 and RGS5 variants with schizophrenia symptom severity (35)
Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function (35)
No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. (35)
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression (35)
Clozapine, negative symptoms, and extrapyramidal side effects. (35)
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia (35)
Neurocognition in early-onset schizophrenia and schizoaffective disorders. (35)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care (35)
Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. (34)
Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample (34)
Psychoneuroendocrinology of schizophrenia. (34)
Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. (34)
Clozapine response in treatment-refractory first-episode schizophrenia (33)
Pharmacologic studies of tardive dyskinesia. (33)
Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. (33)
Comprehensive care of schizophrenia : a textbook of clinical management (33)
Dexamethasone suppression tests in patients with obsessive-compulsive disorder. (33)
Pharmacologic characterization of tardive dyskinesia. (33)
Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation (32)
Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic‐induced weight gain in European and African‐American schizophrenia patients (32)
Single‐voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus (32)
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. (31)
A systematic method for estimating individual responses to treatment with antipsychotics in CATIE (31)
Management of clozapine-induced enuresis. (31)
The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain (31)
Neuropsychological deficits in the early course of first episode schizophrenia. (30)
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. (30)
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition (30)
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients (30)
Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study (30)
Caveat Emptor: Researcher Beware (30)
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode (29)
On the Possible Mechanisms and Predictability of Clozapine-Induced Agranulocytosis (29)
Developmental Effects of Prenatal Cocaine Exposure on 5-HT1A Receptors in Male and Female Rat Offspring (29)
The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness (29)
Major Histocompatibility Complex Associations with Clozapine-Induced Agranulocytosis (29)
Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. (29)
Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking (29)
Analysis of genome-wide CAG/CTG repeats, and at SEF2-1B and ERDA1 in schizophrenia and bipolar affective disorder (29)
Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration (29)
Premature disinhibition of P3 generation in schizophrenia (29)
Methylphenidate decreases regional cerebral blood flow in normal human subjects. (29)
Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats (29)
Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia (28)
Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. (28)
Epidemiology of Tardive Dyskinesia (28)
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. (28)
Incidence and correlates of tardive dyskinesia in first episode schizophrenia (28)
IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness (28)
Schizophrenia: new phenes and new genes. (28)
Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses (28)
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (27)
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine (27)
Prediction of relapse in schizophrenia. (27)
Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. (27)
Obstetric complications predict treatment response in first-episode schizophrenia. (27)
Amphetamine-Induced Fos is Reduced in Limbic Cortical Regions but not in the Caudate or Accumbens in a Genetic Model of NMDA Receptor Hypofunction (27)
The catechol-O-methyl-transferase gene in tardive dyskinesia (27)
Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride (27)
Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity (26)
Secretin for refractory schizophrenia (26)
Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects (26)
Comprehensive Care of Schizophrenia (26)
Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia (26)
Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. (26)
Neurodevelopmental and neurodegenerative hypotheses of schizophrenia: a review and critique (25)
Reconsidering the Classification of Schizophrenia and Manic Depressive Illness — A Critical Analysis and Mew Conceptual Model (25)
Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. (25)
A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia (25)
Akathisia and clozapine treatment. (24)
Developing novel antipsychotic drugs: Strategies and goals (24)
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type (24)
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. (24)
Evidence for a biological hypothesis of obsessive-compulsive disorder. (24)
A predictive model for conversion to psychosis in clinical high-risk patients (24)
The present moment in psychotherapy and everyday life (24)
Ethical principles and practices for research involving human participants with mental illness. (24)
Neuromuscular effects of monoamine oxidase inhibitors. (24)
Drugs of the psychopharmacological revolution in clinical psychiatry. (24)
The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response (24)
Advancing drug discovery for schizophrenia (23)
Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (23)
Shrinks: The Untold Story of Psychiatry (23)
MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. (22)
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study) (22)
Brain volumes in psychotic youth with schizophrenia and mood disorders. (22)
Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial (22)
Clozapine pharmacology and tardive dyskinesia (22)
Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features (22)
Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study (21)
Erratum: Genomewide association for schizophrenia in the CATIE study: Results of stage 1 (Molecular Psychiatry (2008) 13 (570-584) DOI: 10.1038/mp.2008.25) (21)
Caudate Shape Discrimination in Schizophrenia Using Template-Free Non-parametric Tests (21)
756 The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics (21)
Longitudinal perspectives on the pathophysiology of schizophrenia Examining the neurodevelopmental versus neurodegenerative hypotheses (21)
Fat Mass- and Obesity-Associated (FTO) Gene and Antipsychotic-Induced Weight Gain: An Association Study (21)
Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. (21)
A PstI restriction fragment length polymorphism in the 5′ untranslated region of DRD4 is not associated with schizophrenia (20)
Myoclonus during treatment with clozapine and lithium: the role of serotonin. (20)
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. (20)
HLA associations in clozapine-induced agranulocytosis (20)
The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls (20)
Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia (20)
Successful rechallenge with clozapine after eosinophilia. (20)
Substance abuse comorbidity in schizophrenia: editors' introduction. (20)
Aripiprazole versus haloperidol treatment in early-stage schizophrenia. (20)
CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia (20)
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. (20)
The use of clozapine in neurologic disorders. (19)
Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients (19)
Psychiatry: Tasman/Psychiatry (19)
Towards diagnostic markers for the psychoses. (19)
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. (19)
Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO (19)
Variability in response to clozapine: Potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene (19)
Clinical phenomenology. (18)
Brain morphometric comparison of first episode schizophrenia and temporal lobe epilepsy (18)
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain (18)
Neuropsychological studies of first episode schizophrenia (18)
Tardive dyskinesias and drugs (18)
Negative Symptoms in Schizophrenia: Relationship to Positive Symptoms and Outcome (18)
Do white-cell count spikes predict agranulocytosis in clozapine recipients? (18)
Intrinsic Regression Models for Manifold-Valued Data (18)
Follow-up MRI study in first episode schizophrenia Gustav Degreef, M.D., Manzar Ashtari, Ph.D., Howard Wu, B. Med., Michael Borenstein, Ph.D., Jeffrey Lieberman, M.D. Albert Einstein College of Medicine, Hillside Hospital, P.O. Box 38, Glen Oaks, NY 11004 (18)
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain (18)
Handbook of Psychiatric Drugs (18)
Deep resequencing and association analysis of schizophrenia candidate genes (18)
Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. (18)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. (18)
Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population (18)
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial (17)
Improving classification of psychoses. (17)
Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response (17)
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients (17)
Neuroleptic-Induced Movement Disorders: Aging and tardive dyskinesia (17)
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms (17)
Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects (17)
Association Study of GABAA &agr;2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain (17)
Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia (17)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)) (16)
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? (16)
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. (16)
The Effect of Activation Procedures on Neuroleptic-Induced Akathisia (16)
Neuroleptic treatment of elderly patients. (16)
No association of the serotonin transporter polymorphisms 5‐HTTLPR and RS25531 with schizophrenia or neurocognition (16)
Methylphenidate challenge tests and course of schizophrenia. (16)
Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia (16)
Correlates of substance misuse in patients with first‐episode schizophrenia and schizoaffective disorder (16)
Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder (16)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder (15)
Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit gene GRIN2B and clinical response to clozapine (15)
Neurons and Networks: An Introduction to Neuroscience (15)
Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia. (15)
Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia (15)
Getting the Facts Straight About Gun Violence and Mental Illness: Putting Compassion Before Fear (15)
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia (15)
Neuropathological and Brain Imaging Studies in Positive and Negative Schizophrenia (15)
Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family‐based studies (15)
The Power of Hope: A Doctor's Perspective (15)
A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts (15)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (14)
Anticholinergic delirium caused by retreatment with clozapine. (14)
Rib fractures as an unusual complication of severe tardive dystonia. (14)
Time to treatment response in successive episodes of early onset schizophrenia (14)
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case–control and family based study designs (14)
AKT1 and Neurocognition in Schizophrenia (14)
A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. (14)
Conflict of interest-- an issue for every psychiatrist. (14)
A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort (14)
Schizophrenia (maintenance treatment). (14)
Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients (14)
Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians (13)
Clozapine and akathisia (13)
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (13)
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial (13)
ANTIBODIES TO ACETYLCHOLINE RECEPTORS IN TARDIVE DYSKINESIA (13)
Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (13)
The efficacy of amoxapine, maprotiline, and trazodone in comparison to imipramine and amitriptyline: a review of the literature. (13)
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. (13)
Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis (13)
Increased prevalence of the cavum septum pellucidum in MRI scans and postmortem brains of schizophrenic patients (13)
High plasma clozapine levels in tardive dyskinesia. (13)
Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia (12)
A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. (12)
Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. (12)
Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia (12)
The dopamine-serotonin relationship in clozapine response (12)
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. (12)
Association study of the gamma-aminobutyric acid type a receptor γ2 subunit gene with schizophrenia (12)
Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data. (12)
Ziprasidone alternative for olanzapine-induced hyperglycemia. (12)
Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia (12)
Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study (12)
Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group. (12)
Yakovlevian torque is absent in first episode schizophrenia (12)
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain (12)
Signs and symptoms. What can they tell us about the clinical course and pathophysiologic processes of schizophrenia? (12)
Seasonal Admission Patterns in First Episode Psychosis, Chronic Schizophrenia, and Nonschizophrenic Psychoses (12)
Gonadal hormones, sex and behavior. (12)
Pharmacotherapy for Patients with First-Episode, Acute, and Refractory Schizophrenia (12)
Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine (12)
Polydipsia and tardive dyskinesia in chronic psychiatric patients--related disorders? (11)
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. (11)
A polygenic resilience score moderates the genetic risk for schizophrenia (11)
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain (11)
Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings (11)
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (11)
Psychiatry: Behavioral Science and Clinical Essentials (11)
A refined genetic map of the region of chromosome 17 surrounding the von Recklinghausen neurofibromatosis (NF1) gene. (11)
Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care? (11)
Akathisia and clozapine treatment (11)
The prevalence of tardive dyskinesia. (11)
Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. (11)
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo (11)
Ventricular system morphology in first episode schizophrenia: A volumetric study of ventricular subdivisions on MRI (11)
Epidemiological aspects of tardive dyskinesia. (11)
Facial emotion perception and fusiform gyrus volume in first episode schizophrenia (11)
What the CATIE study means for clinical practice. (11)
Evidence for sensitization in the early stage of schizophrenia (10)
Dr. Robinson and Colleagues Reply (10)
Clinical and Pharmacological Studies in Psychiatric Disorders (10)
First-episode psychosis in a managed care setting: clinical management and research. (10)
Adjusted exponentially tilted likelihood with applications to brain morphology. (10)
Erratum: Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs* (10)
Practical applications of recent antipsychotic effectiveness data. (10)
Neural correlates of automatic and controlled auditory processing in schizophrenia. (10)
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia (10)
Erratum: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeuthic approaches (Biological Psychiatry 50:11 (884-897)) (10)
Ethical dilemmas in clinical research with human subjects: an investigator's perspective. (10)
Young Brains on Drugs (10)
Growth hormone response to growth hormone-releasing hormone in schizophrenic patients. (10)
Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness (10)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (9)
Clinical applications of neuroimaging in psychiatry. (9)
Predictors of relapse in schizophrenia (9)
Interpreting the results of the CATIE study. (9)
Attentional modulation of early-stage visual processing in schizophrenia (9)
Synaptophysin and PSD-95 in the human prefrontal cortex from mid-gestation into early adulthood (9)
Handbook of Psychiatric Drugs: Lieberman/Handbook of Psychiatric Drugs (9)
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial (9)
Protein kinase cAMP‐dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic‐induced weight gain (9)
Comparing safety and tolerability of antipsychotic treatment. (9)
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia (9)
Meeting the Mental Health Challenge of the COVID-19 Pandemic (9)
Mood responses of remitted schizophrenics to methylphenidate infusion (9)
Consistency of treatment response across successive psychotic episodes in recent-onset schizophrenia (9)
The behavioral effect of m-Chlorophenylpiperazine (MCPP) and methylphenidate in first-episode schizophrenia and normal controls (9)
Gadolinium-DTPA enhanced gradient echo magnetic resonance scans in first episode of psychosis and chronic schizophrenic patients (9)
What the BRAIN Initiative means for psychiatry. (9)
Measurement of lithium concentrations in human tears. (8)
MDR1 gene in tardive dyskinesia scale scores: Comparison of strategies for quantitative trait haplotype analysis (8)
Alive but not well: the limited validity but continued utility of the concept of schizophrenia (8)
Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia (8)
Syncope associated with the combination of clozapine and enalapril. (8)
Age and treatment related local hippocampal changes in schizophrenia explained by a novel shape analysis method (8)
Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China. (8)
Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study (8)
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation (8)
Linkage analysis of von Recklinghausen neurofibromatosis to DNA markers on chromosome 17. (8)
P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial (8)
Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial (8)
First-episode Psychosis: Part I. Editors' Introduction (8)
Essentials of Schizophrenia (8)
No evidence for parental imprinting of mouse 22q11 gene orthologs (8)
544 Olanzapine versus haloperidol in the treatment of first episode psychosis (8)
Predictors of treatment response and course of schizophrenia (8)
Investigation of melanocortin system gene variants in antipsychotic-induced weight gain (7)
Eliminating the Glass Ceiling in Academic Psychiatry (7)
Spastic dysphonia and denervation signs in a young man with tardive dyskinesia (7)
P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial (7)
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. (7)
Association study between the neurexin‐1 gene and tardive dyskinesia (7)
The impossible dream: can psychiatry prevent psychosis? (7)
Teaching trainees to negotiate research collaborations with industry: a mentorship model. (7)
Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex (7)
Lack of association of NALCN genetic variants with schizophrenia (6)
FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia (6)
0394 CLINICAL EFFECTIVENESS AND PREDICTORS OF TREATMENT NON-ADHERENCE: COMPARISON OF OLANZAPINE, QUETIAPINE, AND RISPERIDONE IN FIRST-EPISODE PSYCHOSIS (6)
Age and Treatment Related Local Hippocampal Changes in Schizophrenia Explained by a Novel Shape Analysis Method (6)
553 Pilot study of atypical antipsychotic agents in first episode schizophrenia (6)
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach (6)
Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis (6)
Clozapine and tardive dyskinesia: Prospective data (6)
Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia (6)
Psychiatrists Diagnosing the President - Moral Imperative or Ethical Violation? (6)
TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. (6)
Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine (6)
A VOLUMETRIC MRI STUDY OF LIMBIC STRUCTURES IN CHRONIC SCHIZOPHRENIA ‐ RELATIONSHIP TO PSYCHOPATHOLOGY (6)
New-Onset Tardive Dyskinesia in Patients With First-Episode Psychosis Receiving Risperidone or Haloperidol (6)
Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain (6)
Lack of association between HTR4 gene polymorphisms and schizophrenia in case–control and family-based samples (6)
Advances in the Management of Treatment- Resistant Schizophrenia (6)
Schizophrenia, VI: Treatments. (6)
Effects of the D 1 Dopamine Receptor Agonist Dihydrexidine ( DAR-0100 A ) on Working Memory in Schizotypal Personality Disorder (6)
A Selective Review of Recent Advances in the Management of Tardive Dyskinesia (6)
Psychosis and genes with trinucleotide repeat polymorphism (6)
Clinical Research in the Age of Neuroscience (6)
Structural neuroimaging of psychiatry disease: Reliable and efficient automatic brain tissue segmentation for increased sensitivity (6)
Predictors of outcome in schizophrenia: the concept of time (5)
P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment (5)
MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA (5)
Mismatch negativity (MMN) in first episodic and chronic schizophrenic subjects (5)
Dr. Lieberman and Colleagues Reply (5)
Pocket companion to accompany psychiatry (5)
Chapter 3.5 – Atypical antipsychotic drugs and stress (5)
Unrelated agranulocytosis in a patient taking clozapine. (5)
Psychiatry: Nothing to Be Defensive About (5)
Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder (4)
Psychotic symptoms in mass shootings v. mass murders not involving firearms: findings from the Columbia mass murder database. (4)
Biologic indices of heterogeneity in schizophrenia: Relationship to psychopathology and treatment outcome (4)
From known to unknown; old to new: can lesion studies inform psychiatry about mental illness in the 21st century? (4)
Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective (4)
The moral imperatives of medical research in human subjects. (4)
Schizophrenia‐associated gene dysbindin‐1 and tardive dyskinesia (4)
Course and predictors of weight gain in people Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine with first-episode psychosis treated with olanzapine (4)
Brain Regions Associated With Internalizing and Externalizing Psychiatric Symptoms in Patients With Penetrating Traumatic Brain Injury. (4)
Sedative–Hypnotic Agents (4)
Decline of dopamine: effects of age and acute neuroleptic challenge. (4)
Antipsychotic Trials in Schizophrenia: Study design and protocol development process (4)
Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective (4)
Antipsychotic Trials in Schizophrenia: List of contributors (4)
Behavioral responses to a dopaminergic challenge in obsessive-compulsive disorder (4)
Introduction. Quetiapine: A 5-Year Update (4)
Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (4)
Intrinsic Regression Models for Medial Representation of Subcortical Structures (4)
Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical? (4)
Back to the future: Research renewed on the clinical utility of psychedelic drugs (4)
Starting a Career in Psychiatric Research (4)
Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis (3)
Schizophrenia Spectrum and Other Psychotic Disorders (3)
Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis (3)
Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone (3)
Neuroimaging, neurodevelopment, and schizophrenia (3)
Psychiatry Embraces Patient-Centered Care (3)
Searching for the neuropathology of schizophrenia: neuroimaging strategies and findings. (3)
CT morphology and short term outcome in schizophrenia (3)
Neurodevelopment and Schizophrenia: Neurodegenerative models of schizophrenia (3)
The deficit state in a prospective study of first-episode schizophrenia (3)
Prospective MRI study of caudate pathomorphology in first episode schizophrenia (3)
Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia † (3)
An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS (3)
S shape analysis of neuroanatomical structures based on medial models (3)
Prevalence of tardive dyskinesia in elderly samples. (3)
Age of onset in schizophrenia (3)
417. Auditory event-related potentials (ERP) in first episode and chronic schizophrenia (3)
The Dangerous Case of Psychiatrists Writing About the POTUS’s Mental Health (3)
Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia (3)
Independence of morphologic markers in schizophrenia (3)
Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study (3)
Gender differences in the presentation, course, and outcome of first episode schizophrenics (2)
Revised PORT recommendations. (2)
S-43-4 Evidence for sensitization in the early stage of schizophrenia (2)
Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia (2)
Deficits in mismatch negativity in schizophrenia: Predictor of outcome or result of illness progression? (2)
Plasma homovanillic acid in first-episode schizophrenia: Psychopathology and treatment response (2)
S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (2)
Tardive dyskinesia induced by risperidone? [9] (2)
ReviewCatching Up on Schizophrenia : Natural (2)
Deep Learning Substitutes Gadolinium in Detecting Functional and Structural Brain Lesions with MRI (2)
P.3.e.017 Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia (2)
A single estimate of separate within-individual correlations: applications in psychopharmacology. (2)
Tricyclic Antidepressant Drug and Metabolite Levels in Chronic Renal Failure (2)
Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology (2)
Shrinks: The Untold Story of Psychiatry, by Jeffrey A. Lieberman, M.D., with Ogi Ogas: A Critical Discussion (2)
Novel histamine H1 gene polymorphism and clozapine-induced weight gain (2)
Recent Advances in the Clinical Use of Atypical Antipsychotics (2)
Prevention of relapse in schizophrenia. (2)
Back to the Future - The Therapeutic Potential of Psychedelic Drugs. (2)
Neopterin and biopterin CSF levels in tardive dyskinesia after clozapine treatment (2)
A study using gadopenetetate dimeglumine enhanced MRI scans in schizophrenia (2)
Dopamine Pathophysiology in Tardive Dyskinesia (2)
Response to the presidential address. (2)
74. Incidence of suicide in a research study of first episode schizophrenia (2)
Mismatch negativity, neuropsychological deficits and psychopathology in chronic schizophrenia (2)
Temporal limbic structure volumes and psychopathology in chronic schizophrenia (2)
Marijuana smokers at clinical high-risk for schizophrenia exhibit an enhanced subjective, behavioral and physiological response to smoked marijuana (2)
Improving Mental Health Care in America: An Opportunity for Comprehensive Reform (2)
Search for unstable DNA in schizophrenia (2)
An interview with Jeffrey A. Lieberman: Tardive Dyskinesia. [interview by Sussman Norman]. (2)
Negative Symptoms and Cognitive Deficits (1)
Bipolar disorder: A syndrome in evolution (1)
Training the Psychiatrist of the Future (1)
Schizophrenia: comments on genes, development, risk factors, phenotype, and course. (1)
Pharmacotherapy of Schizophrenia (1)
Dysphoria associated with methylphenidate infusions. (1)
POLYDIPSIA, TARDIVE DYSKINESIA, AND DOPAMINE SUPERSENSITIVITY. AUTHORS' REPLY (1)
1051 – Lurasidone In The Treatment Of Early-stage Schizophrenia: a Post-hoc Analysis Of Three Pooled Acute Treatment Studies (1)
First-Episode Part II. Editors' Introduction (1)
Correlates of course and outcome in first-episode schizophrenia (1)
Comparative effectiveness of antipsychotic drugs. Commentary (1)
Milestones in the History of Schizophrenia. A Comprehensive Chronology of Schizophrenia Research: What Do We Know and When Did We Know It (1)
A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise (1)
Ethics of Drug Discontinuation Studies in Schizophrenia-Reply (1)
Schizophrenia Spectrum and Other Psychotic Disorders (1)
P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (1)
Our future is now. (1)
79-4 Evidence for sensitization in the early stage of schizophrenia (1)
Is bromocriptine a dopamine antagonist treatment? (1)
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures (1)
Predictors of response to clozapine in chronic schizophrenia (1)
713 Obstetric complications in schizophrenia, affective disorder and normal controls (1)
Change, Challenge and Opportunity: Psychiatry in Age of Reform and Enlightenment (1)
452 Obstetric complications and brain MRI findings in schizophrenia (1)
Marijuana Legalization and Young Brains: Time for Serious Study (1)
DISPUTING PSYCHIATRY'S REDEFINITION. AUTHORS' REPLY (1)
Five year follow-up of outcome in a prospective study of first-episode schizophrenia at Hillside hospital (1)
Mesiotemporal volumes and asymmetry in first episode schizophrenics: A baseline and follow-up study (1)
Genomic dissection of bipolar disorder and schizophrenia including 28 subphenotypes (1)
Dr. Penn and Colleagues Reply (1)
Memory deficits in first episode schizophrenia: Beyond impaired acquisition (1)
Management of victims of torture (1)
Antipsychotic Trials in Schizophrenia: Violence in schizophrenia: prevalence, correlates, and treatment effectiveness (1)
The Ketamine Challenge: When Practice Leaps Ahead of Science (1)
Drs. Lieberman, Javitch, and Moore Reply (1)
Drs. Umbricht and Lieberman Reply (1)
746 First episode schizophrenia and borna disease virus (1)
Ventricular volumes in patients with temporal lobe epilepsy and psychosis (1)
Antipsychotic adverse reactions in schizophrenia: A pharmacogenetic study of weight gain and tardive dyskinesia. (1)
The Rapid Rise in Investment in Psychedelics-Cart Before the Horse. (1)
579 Obstetric complications predict treatment response in first episode schizophrenia (1)
Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients (1)
Second International Symposium on the Economic and Social Costs of Substance Abuse (1)
Social adjustment and outcome in first episode schizophrenia (1)
The dopamine-serotonin relationship in clozapine response (1)
PATHOPHYSIOLOGY OF SCHIZOPHRENIA: Neurodevelopmental and Neurodegenerative Processes (1)
Erratum: The evaluation and treatment of first-episode psychosis (Schizophrenia Bulletin (1997) 23 (653-661)) (1)
BORDERLINE PERSONALITY DISORDER : INTERFACE WITH MOOD AND OTHER AXIS I DISORDERS — (1)
Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study (1)
Olanzapine versus haloperidoi treatment in first-episode psychosis (1)
Robert Spitzer: A Psychiatrist for the Ages (1)
Hypothesis and hypothesis testing in the clinical trial. (1)
Neonatal neurosteroid administration alters adult parvalbumin immunoreactivity in rat prefrontal cortex and thalamus (1)
Growth hormone response to growth hormone releasing factor in schizophrenia (1)
Antibodies to Acetylcholine Receptors in Patients with Tardive Dyskinesia (1)
Anti-viral properties of antipsychotic medications in the time of COVID-19 (1)
Comprar Essentials of Schizophrenia | T. Scott Stroup | 9781585624010 | American Psychiatric Publishing (1)
Teaching Trainees to N egotiate R esearch C ollaborations W ith Industry: A M entorship M odel (1)
New insights into classical issues in schizophrenia (1)
Neuropsychological profiles of first episode schizophrenia (1)
Foreword (1)
Diagnostic stability in patients followed from their first episode of schizophrenia or schizoaffective disorder (1)
Investigation of olanzapine-associated weight gain in first episode subjects (1)
Caudate nucleus volume and cognitive deficit in first episode psychosis (1)
Liver enzyme CYP2D6 gene and tardive dyskinesia. (1)
DSM Crosses the Finish Line (1)
Neuropsychological responses to stimulant challenge in schizophrenia (1)
33. Dopaminergic modulation of frontal activity: Involvement in cocaine addiction (1)
NMDAR and D1 receptor genes in the response to clozapine treatment and negative symptoms (1)
Memory impairment in first episode schizophrenia (1)
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. (0)
TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA (0)
tardive dyskinesia. Spastic dysphonia and denervation signs in a young man with (0)
Hippocampal Glutamate and Positive Symptom Severity in Clinical High Risk for Psychosis. (0)
Personalized Medicine for Schizophrenia (0)
P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies (0)
Reduced mesiotemporal lobe volumes and asymmetries in schizophrenia (0)
S-9-4 Treatment and consequences of relapse in schizophrenia (0)
Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) (0)
73. BCL-2 protein reduced in schizophrenic temporal cortex (0)
Group therapy with schizophrenia patients. Authors' reply (0)
Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS) (0)
Back to the Future: Psychiatry’s Re-Commitment to Public Mental Health (0)
Deficits in generation of auditory event-related potentials, neuropsychological performance and psychopathology in chronic schizophrenia (0)
Stability of visual fixation in schizophrenics and normal controls (0)
389 Neuroanatomic abnormalities in the psychoses: Diagnostic specificity or severity spectrum? (0)
Effects of chronic treatment with typical and atypical antipsychotic drugs on the caudate nucleus in the rat (0)
681 Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia (0)
Pharmacogenetic dissection of central and peripheral candidate genes in atypical antipsychotic-induced weight-gain (0)
Poster #M41 HIGH RESOLUTION BASAL STATE FUNCTIONAL IMAGING REVEALS A SUBCORTICAL-CORTICAL SPREADING PATTERN OF FUNCTIONAL ABNORMALITY IN CLINICAL HIGH-RISK PATIENTS WHO PROGRESS TO PSYCHOSIS (0)
THE D1 RECEPTOR AND COGNITION AND TRIAL OF A NOVEL D1 AGONIST IN THE SCHIZOPHRENIA SPECTRUM (0)
Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients (0)
Superior temporal gyrus volume and asymmetry in first-episode schizophrenia (0)
Temporal lobe epilepsy and psychosis (0)
680 Auditory event-related potentials (ERP) in first episode and chronic schizophrenia (0)
The effect of clozapine treatment on mismatch negativity (0)
Schizophrenia Spectrum and Other Psychotic Disorders (0)
771 Neurodevelopmental risk for tardive dyskinesia (0)
Mismatch negativity during treatment with clozapine (0)
Antipsychotic Tn-DaIs in Schizophrenia The CA TI E Project (0)
50 Years After: Will We Realize JFK’s Vision for Mental Health Care? (0)
Behavioural effects of IV MCPP in schizophrenia (0)
Clinical Phenomenology CHAIRPERSON (0)
84. Clinical correlates of structural brain abnormalities in schizophrenia (0)
UNRELATED AGRANULOCYTOSIS IN A PATIENT TAKING CLOZAPINE. AUTHOR'S REPLY (0)
APA 2014: Changing the Practice and Perception of Psychiatry (0)
The valid assessment and diagnosis of akathisia is of great importance for antipsychotic treatment and for the evaluation of the side-effects of neuroleptics (0)
THE DEFINITION OF AN ATYPICAL ANTIPSYCHOTIC (0)
This Excerpt Is from Chapter 104 Complementary and Alternative Treatments in Psychiatry (0)
Brain morphology, dopamine and outcome in first episode schizophrenia (0)
Pharmacogenetics of antipsychotic induced weight gain and tardive dyskinesia (0)
P.1.a.002 Glial cell-derived neurotrophic family (GFR) alpha 1 receptor polymorphisms and weight change during clozapine treatment (0)
Jay Scully Deserves Our Thanks For a Job Well Done (0)
BIOLOGIC INDICES OF HETEROGENEITY IN SCHIZOPHRENIA: RELATIONSHIP TO PSYCHOPATHOLOGY AND TREATMENT OUTCOME (0)
379. Symptom dimensions in first-episode schizophrenia: A longitudinal, confirmatory factor analytic study (0)
Effectiveness and efficacy: Staying on treatment and symptom reduction (0)
Alexander H Glassman (0)
Editorial (0)
The Truth About Psychiatry and Health Care Insurance (0)
Antipsychotic Trials in Schizophrenia: Introduction (0)
"It's Not What You Think: An Evolutionary Theory of Spiritual Enlightenment" (0)
Comprar Antipsychotic Trials in Schizophrenia | T. Scott Stroup | 9780521895330 | Cambridge University Press (0)
P.2.085 Amphetamine and stress-induced behaviors and c-Fos expression in a genetic model of NMDA receptor hypofunction (0)
Contents Vol. 2, 2016 (0)
35. Neuropsychological prediction of functional outcome in first-episode schizophrenia (0)
118. The Challenges of Testing D1 Agonists in Schizophrenia (0)
Cortical-subcortical dysconnectivity expressed by attenuated cortical c-fos induction by acute amphetamine treatment or acute swim stress in mice with reduced NMDA receptor1 expression (0)
EVIDENCE FOR SENSITIZATION IN EARLY STAGE OF SCHIZOPHRENIA (0)
Front & Back Matter (0)
Contents Vol. 24, 2002 (0)
Prepubertal Psychosis: A Case Control Study (0)
Brain morphology in first episode schizophrenia (0)
PHOSPHODIESTERASE 4B GENETIC VARIANTS ARE NOT ASSOCIATED WITH ANTIPSYCHOTIC-INDUCED TARDIVE DYSKINESIA (0)
Dr. Keefe and Colleagues Reply. (0)
WC1F SPI-A DIMENSIONS: OVERSTRAIN AND ITS RELATION TO STRESS REACTIVITY AND SOCIAL FUNCTION IN PRODROMAL PATIENTS (0)
Schizophrenia research series: from molecule to public policy. (0)
Gender differences in clozapine treated schizophrenic patients (0)
A 22-YEAR-OLD MALE WITH A MANIC EPISODE — (0)
233. Effects of dopaminergic modulation on trait-like redundancy in schizophrenia (0)
Comparison of behavioral effects of olanzapine and clozapine in a genetic model of NMDA receptor hypofunction (0)
Pathophysiology in the clinical course of schizophrenia (0)
145. Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors (0)
Subject Index Vol. 24, 2002 (0)
437. Language and superior temporal gyrus volumes in schizophrenia (0)
Influence of the risk for psychosis on facial affect recognition and threat evaluation in marijuana users (0)
Thank You for the Opportunity (0)
SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response (0)
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. (0)
CT morphology and outcome in schizophrenia (0)
104. Antipsychotic Drugs (0)
Schizophrenia Study: What Did We Learn? (0)
Medical Conditions That Can Masquerade as Schizophrenia (0)
The smartest person in the room: Donald F. Klein, M.D. (1928–2019) (0)
Anxiety Disorders: Foreword by Jeffrey A. Lieberman (0)
Antipsychotic Trials in Schizophrenia: Implications for research design and study implementation (0)
Treatment of Schizophrenia: Current Capability, Future Promise (0)
Predictors of tardive dyskinesia in first episode schizophrenia (0)
20-3 The psychobiology of first episode schizophrenia (0)
Incidence and correlates of TD in first episode schizophrenia (0)
T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2 (0)
The association of premorbid function in schizophrenia with baseline symptomatology, treatment response and medication side-effects (0)
Biochemical effects of clozapine in schizophrenia (0)
Neuromuscular effects of monoamine oxidase inhibitors. (0)
Medicine and the Mind. (0)
Is frontal lobe dysfunction really generalized deficit in schizophrenia? (0)
Poster #T48 INVESTIGATION OF THE PRO-MELANIN-CONCENTRATING HORMONE GENE IN ANTIPSYCHOTIC INDUCED WEIGHT GAIN (0)
Drug-Induced and Other Acute Psychoses in an Emergency-Room Setting (0)
Early Detection of Schizophrenia: The Time Is Now (0)
M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN (0)
Books Received (0)
P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study (0)
Interview: In search of the pathophysiology and prevention of schizophrenia (0)
What CATIE Found: Results From the Schizophrenia Trial (0)
Fixed-False Beliefs (0)
IPS to Feature Patrick Kennedy, Celebrate Community Psychiatry (0)
Biological predictors of antipsychotic treatment response (0)
48-1 Extrapyramidal signs in dyskinesia in first episode schizophrenia (0)
Using Psychotherapy and Medications to Treat a Teenager with Prodromal Symptoms (0)
92-2 Co-morbidity issues in the treatment of schizophrenia (0)
What is the nature of the eye movement dysfunctions found in schizophrenics? (0)
FINDINGS OF PHASE 3 OF THE CATIE SCHIZOPHRENIA TRIAL (0)
GENETIC ASSOCIATION ANALYSIS OF THE GFR ALPHA GENES WITH SCHIZOPHRENIA AND CLOZAPINE RESPONSE (0)
Schizophrenia Outcomes Functioning Interview--Patient Version (0)
SU86 VALIDATION STUDY IN TWO GENOME-WIDE SIGNIFICANT RISK VARIANTS FOR ANTIPSYCHOTIC INDUCED WEIGHT GAIN (0)
Dr Kantrowitz and Colleagues Reply. (0)
71. Atypical antipsychotic medication in the treatment of first episode schizophrenia (0)
Longitudinal course of brain morphology in first episode schizophrenia (0)
Herbert D. Kleber (0)
Cognitive Enhancers and Treatments for Alzheimer's Disease (0)
Collaborative Care: An Integral Part of Psychiatry’s Future (0)
Brain volume correlated with neuropsychological ability in first episode schizophrenia (0)
No association between the COMT VAL158MET polymorphism and antipsychotic response in schizophrenia (0)
Contents continued (0)
378. Working memory deficits in schizophrenia persist after matching on task difficulty (0)
Dr. Bilder and Colleagues Reply (0)
Antipsychotic drugs: The current limitations and future promises (0)
The Capgras Delusion (0)
Neurosteroid modulation of GABAergic neurotransmission in the central amygdala (0)
Will the Government Do the Right Thing (0)
Cultivating the Next Generation of Psychiatrists (0)
A Scientific Pioneer of Psychiatry. (0)
117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment (0)
Schizophrenia Outcomes Functioning Interview--Informant Version (0)
Pathophysiology of Schizophrenia (0)
Psychiatric diagnosis: Exploration of biological predictors: Edited by Hagop S. Akiskal and William L. Webb. New York, S. P. Medical and Scientific Books, 1978 (0)
257 Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy (0)
Research report A in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function (0)
Structure-function relations in first episode schizophrenia (0)
T38 Preliminary Model For The Genetic Prediction Of Clozapine Response (0)
Electroconvulsive Therapy: A Potent Therapy for Major Depressive Disorder (0)
454 Absence of overall cortical and subcortical volume differences among major mental disorders (0)
Solving the Mystery of Military Mental Health: A Call to Action (0)
Quantitative features of eye movement dysfunctions in schizophrenics (0)
446 Parcellation of the frontal lobes in first-episode schizophrenia (0)
Richard Resnick (0)
Alpha-1A adrenergic (ADRA1A) and serotonin 6 (HTR6) receptor gene polymorphisms and clinical response to clozapine (0)
423 MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia (0)
72. Longitudinal neuropsychological change in first-episode schizophrenia (0)
What It Means to Be President (0)
Limbic system morphology in schizophrenia: A comparison of new post mortem and MRI data (0)
SPASTIC DYSPHONIA, DENERVATION AND DYSKINESIA (0)
Politics of Psychiatry and Mental Health Care (0)
Dr. Volavka and Colleagues Reply (0)
Impaired Functioning and Downward Shift in Functioning in Schizophrenia (0)
A genetic signature for complex psychiatric diseases (0)
Ventricular shape of monozygotic twins discordant for schizophrenia reflects vulnerability (0)
Clozapine: Comparative response and morbidity (0)
Measuring outcome priorities and preferences Measuring outcome priorities and preferences in people with schizophrenia in people with schizophrenia (0)
Drs. Stroup, Rosenheck, Essock, and Lieberman Reply (0)
Questioning DST normalization as a guide to tricyclic discontinuation. (0)
Clozapine and Treatment-Refractory Illness (0)
Neuroleptic-Induced Movement Disorders: Development of novel antipsychotic drugs with reduced extrapyramidal side effects (0)
Academic Highlights: Practical Applications of Recent Antipsychotic Effectiveness Data. [CME] (0)
Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia (0)
High-impact rare genetic variants in severe schizophrenia. (0)
VKučinskas-2001-2016 (0)
149 Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia (0)
Reviewers for Neuropsychiatric Disease and Treatment, Volume 1, 2005 (0)
The Role of Psychiatrists in the Brave New World of Health Care (0)
F181. A Randomized, Single-Blind, Parallel-Group Study to Evaluate the Effects of TS-134 on Ketamine- Induced Bold Signals in Resting fMRI in Healthy Adult Subjects (0)
Molecular genetics of neurodevelopment and treatment response in psychosis (0)
Visual working-memory dysfunction and P3 in schizophrenia (0)
Psychiatric Ramications of the COVID-19 Pandemic (0)
Frontolimbic mechanisms for perceptual and response classification in schizophrenia (0)
PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN (0)
262. Methylphenidate effects on verbal fluency in schizophrenia (0)
Abnormal brain morphology in MRI scans of first episode schizophrenics associated with poor treatment response (0)
Time to onset of extrapyramidal symptoms in first episode of psychosis (0)
Auditory Hallucinations and Religious Delusions (0)
Behavioral neurochemistry: Jose M. R. Delgado and Francis V. DeFeudis (eds). Spectrum Publications, New York (0)
We've come a long way. (0)
Ellen Stover (0)
Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or Panacea (0)
Raising the standard of care for schizophrenia is an achievable goal (0)
TC2B TEMPORAL ASSOCIATION OF CANNABIS USE AND PERCEPTUAL DISTURBANCES IN PRODROMAL PATIENTS (0)
Violence in Schizophrenia (0)
Comprar Psychiatry, 2 Volume Set | Prof. Kian Fan Chung | 9780470065716 | Wiley (0)
Computerized neurocognitive assessment: Clinical trials and FMRI applications (0)
F103NEW GENETIC FINDINGS IN TARDIVE DYSKINESIA: FROM CYP2D6 TO C4 (0)
PM389. Preliminary Genetic Model Predicting Clozapine Response (0)
Response to "Unrelated agranulocytosis in a patient taking clozapine". (0)
APA Successful in Attaining Higher Work Values for Psychiatry (0)
Antipsychotic Trials in Schizophrenia: Conclusion and implications for practice and policy (0)
Response to Kornfeld. (0)
Parkinsonism in neuroleptic naive schizophrenic patients (0)
Bibliography B IPOLAR D ISORDER (0)
The NIMH-CATIE Schizophrenia Study: What Did We Learn? (0)
Motor performance in schizophrenia: Treatment effects and predictive validity (0)
Electroconvulsive Therapy in Schizophrenia (0)
Premature disinhibition of visual P3 in schizophrenia (0)
Comprar Solid State Polymerization | Allan Tasman | 9780470084182 | Wiley (0)
Essential Psychiatry: Biological treatments for psychotic disorders (0)
A chronometric analysis of executive deficits in acute and stable phases of first episode schizophrenia (0)
Cumulative sojourn time in longitudinal studies: a sequential imputation method to handle missing health state data due to dropout. (0)
Drs. Lieberman and Rush Reply (0)
Lost In Translation: What We Really Learned From CATIE (0)
GLIAL CELL LINE–DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 2 IS ASSOCIATED WITH TARDIVE DYSKINESIA (0)
The First-Episode of Psychosis and Suicide in Schizophrenia (0)
Delayed matching to sample in first episode schizophrenia (0)
Decreased PAR-4 in the temporal cortex of subjects with schizophrenia (0)
Change, Challenge, and Opportunity: Psychiatry in the Age of Health Care Reform (0)
Interpreting the Results of the CATIE Study (0)
70. Baseline and follow-up mesiotemporal volumes in first episode schizophrenics (0)
AOT and Long-Term Use of Antipsychotics. (0)
The Many Clinical Phases of Early Psychosis and the Importance of Psychoeducation and Medication Management (0)
50. Ziprasidone blocks ketamine-induced brain metabolic activation (0)
Hiding in Plain Sight: The Public Health Crisis of Suicide (0)
Prevention of relapse in schizophrenia Prof. A.C. Altamura. Department of Psychiatry, Istituto Scienze Biomediche, University of Milan, Ospedale L. Sacco, Via G.B. Grassi, 75-20175-Milano, Italy (0)
498. Chronic haloperidol administration significantly increases striatal volumes in the RAT (0)
Duration of illness and treatment effects on Duration of illness and treatment effects on hippocampal volume in male patients with hippocampal volume in male patients with schizophrenia (0)
Plasma levels of Fluphenazine and prolactin in maintenance treatment of schizophrenia (0)
Author's reply (0)
Dose occupancy relationship for a D1 agonist using [11C] NNC 112 in primates (0)
Contents of the American Journal of Psychiatry (0)
100. Differential effects of typical and atypical antipsychotic medication on plasma prolactin levels (0)
Change, Challenge, and Opportunity: Psychiatry Through the Looking Glass of Research (0)
68. Temporal lobe structure angulation in first-episode schizophrenia (0)
Comparative effectiveness of antipsychotic drugs. Authors' reply (0)
68-6 Atypical antipsychotic drug treatment in the early stages of schizophrenia (0)
Drugs for Treating Substance Abuse Disorders (0)
Clinical Trial of New Drug for Schizophrenia. Reply. (0)
Clozapine response in chronic schizophrenia not associated with brain morphology on MRI: A preliminary report (0)
Understanding and Caring for People with Schizophrenia (0)
The neurobiology of auditory and visual perceptual abnormalities in a clinical high-risk for psychosis cohort: A pilot morphometric magnetic resonance imaging study. (0)
Sulcal volume and prominence in first episode schizophrenia (0)
The Heritability of Schizophrenia and Dealing with Having a Family Member with Schizophrenia (0)
144. Cytokine regulation of embryonic cortical neuron survival: implications for schizophrenia (0)
Time to Re-Engage With Pharma? (0)
Poster Session I (0)
F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS (0)
An exploratory magnetic resonance imaging study of suicidal ideation in individuals at clinical high-risk for psychosis (0)
Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)) (0)
Sensitization in the pathogenesis and natural history of schizophrenia (0)
394 Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia (0)
273. Neuropsychological correlates of prefrontal volume in schizophrenia (0)
Persecutory Delusions and the Transition from Clinical High-Risk to Syndromal Psychosis (0)
Comparable dopamine 2 receptor occupancy. Authors' reply (0)

This paper list is powered by the following services:

Other Resources About Jeffrey Lieberman

What Schools Are Affiliated With Jeffrey Lieberman?

Jeffrey Lieberman is affiliated with the following schools: